Financial PerformanceMetagenomi reported a 2023 net loss of $68.3 million, highlighting ongoing financial challenges.
Partnership ConcernsThe PH1 program with Moderna was not a commercially viable opportunity, casting doubts on the value of the partnership.
Stock Valuation RisksAnalyst sets a bearish $7 price target on MGX stock due to mixed non-human primate data, slow progression to clinical trials, and a recent setback in its platform technology.